The estimated Net Worth of John J Orloff is at least $11.7 Миллион dollars as of 8 June 2018. John Orloff owns over 2,115 units of Alexion Pharmaceuticals stock worth over $5,820,113 and over the last 8 years he sold ALXN stock worth over $250,691. In addition, he makes $5,626,740 as Executive Vice President и Head of Research and Development at Alexion Pharmaceuticals.
John has made over 1 trades of the Alexion Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,115 units of ALXN stock worth $250,691 on 8 June 2018.
The largest trade he's ever made was selling 2,115 units of Alexion Pharmaceuticals stock on 8 June 2018 worth over $250,691. On average, John trades about 141 units every 0 days since 2016. As of 8 June 2018 he still owns at least 31,790 units of Alexion Pharmaceuticals stock.
You can see the complete history of John Orloff stock trades at the bottom of the page.
Dr. John J. Orloff M.D. serves as Executive Vice President, Head of Research and Development of the Company. Dr. Orloff is Executive Vice President, Head of Research & Development of Alexion. Dr. Orloff is focused on strengthening Alexion’s clinical pipeline and research programs, enhancing research and development productivity, overseeing regulatory and medical affairs, and supporting business development. Dr. Orloff has 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. Prior to joining Alexion in June 2017, Dr. Orloff served as Executive Vice President, Head of Research & Development at Novelion from November 2016 to May 2017, where he currently sits on the Board of Directors. From July 2015 to July 2016, he served with Baxalta as Global Head of R&D and Chief Scientific Officer, where he advanced the company’s pipeline and oversaw regulatory approval of 10 unique products and two devices. He also held executive R&D roles with Baxter International from July 2014 to June 2015, Merck Serono from January 2014 to May 2014, Novartis from April 2003 to October 2013 and Merck Research Laboratories. Prior to joining the biopharmaceutical industry in 1997, Dr. Orloff was with the Yale School of Medicine for seven years. Dr. Orloff received a Bachelor of Arts from Dartmouth College, and a M.D. from the University of Vermont College of Medicine. He completed his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.
As the Executive Vice President и Head of Research and Development of Alexion Pharmaceuticals, the total compensation of John Orloff at Alexion Pharmaceuticals is $5,626,740. There are 1 executives at Alexion Pharmaceuticals getting paid more, with Ludwig Hantson having the highest compensation of $18,948,000.
John Orloff is 62, he's been the Executive Vice President и Head of Research and Development of Alexion Pharmaceuticals since 2017. There are 6 older and 12 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.
John's mailing address filed with the SEC is 1800 W Georgia St, Vancouver, BC V6G 2L3, Canada.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell и Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: